Introduction {#Sec1}
============

Corona Virus Disease (COVID-19) is a new disease, which within 3 months of its origin, has now spread to more than two hundred countries and territories around the world, affecting more than 4,342,000 people and caused more than 292,000 deaths, as of 13 May 2020 \[[@CR1]\]. On 11 March 2020, the World Health Organization (WHO) had declared COVID-19 a pandemic because of alarming levels of its spread and severity \[[@CR2]\]. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is sufficiently genetically divergent from SARS-CoV to be considered a new human-infecting betacoronavirus \[[@CR3]\]. It mainly affects the respiratory tract, and the illness ranges in severity from asymptomatic or mildly symptomatic to severe or critical disease. Although the current estimate of the case fatality rate of COVID-19 is \< 5%, up to 15% to 18% of patients may become severe or critically ill, some of them requiring intensive care unit (ICU) care and mechanical ventilation \[[@CR4]\].

Since COVID-19 is a new disease, knowledge about this disease is still incomplete and evolving. Apart from the respiratory system involvement, many case series have also reported variable involvement of gastrointestinal (GI) and hepatic systems. However, most of these case series have small sample size, and the data in these are heterogenous and conflicting. In addition, the relationship of GI and hepatic involvement with the severity and outcome of COVID-19 is also not clear.

Hence, this systematic review and meta-analysis was conducted with the following objectives: (1) to study the frequency of GI and hepatic manifestations in COVID-19, and (2) to determine whether GI or hepatic manifestations are associated with severe clinical course of COVID-19.

Methods {#Sec2}
=======

Since this is a systematic review and meta-analysis, an institutional review board or an ethics committee approval was not required. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and MOOSE (Meta-analysis of Observational Studies in Epidemiology) guidelines were consulted during the stages of design, analysis, and reporting of this meta-analysis \[[@CR5], [@CR6]\]. The protocol of this meta-analysis is registered with the International Prospective Register of Systematic Reviews (PROSPERO) vide registration number CRD42020179482 and is available in full on the NIHR (National Institute for Health Research) website (<https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020179482>).

Study selection {#Sec3}
---------------

Relevant papers in English language were searched in PubMed database using the following keywords: "2019-nCoV," "nCoV-2019," "novel Coronavirus 2019," "SARS-CoV-2," "COVID-19," "coronavirus," "coronavirus covid-19," and "corona virus." Since the first report of COVID-19 disease was published on 31 December 2019 \[[@CR7]\], we limited our search to articles published since 1 January 2020. The last search was performed on March 25, 2020. Since there is a high likelihood of duplicate publications on COVID-19 \[[@CR8]\], especially, the same set of patients being reported in English as well as Chinese or other languages, we restricted our search to papers published in English language only. For the same reason, we restricted our search to PubMed database only and did not search other databases.

The eligibility criteria for the inclusion of studies were as follows:The studies should be in English language.The studies should be published in full; studies published only in abstract form (such as conference abstracts) were excluded.The study design should be retrospective or prospective, observational, or case-control study with data on GI and/or hepatic manifestations of COVID-19 disease. Interventional studies such as controlled or uncontrolled drug trials were excluded. Case reports, meta-analyses, and systematic reviews were also excluded.The participants should be adult patients with COVID-19 disease. Studies describing exclusively pediatric population were excluded; however, studies which had both adult and pediatric patients were included. Studies describing exclusively pregnant women were also excluded.

Data extraction {#Sec4}
---------------

The following data were extracted from each study: date of online publication, number of patients, study setting, demographic data, comorbidities, presenting symptoms (including GI symptoms), laboratory features (including liver function tests), number of patients having severe and good clinical course. The following criteria were used to identify patients having "severe clinical course":Patients requiring ICU carePatients developing acute respiratory distress syndrome (ARDS), shock, respiratory failure, or those requiring mechanical ventilation as defined according to the guidance of the WHO for COVID-19 \[[@CR9]\]Patients categorized as severe or critical groups according to the diagnostic and treatment guideline for SARS-CoV-2 issued by the National Health Commission of the People's Republic of China (version 3--5) \[[@CR10], [@CR11]\]Patients not surviving

Patients not having any of the features of "severe clinical course" were categorized into "good clinical course." The baseline clinical and laboratory features of patients with severe clinical course and good clinical course were tabulated separately and compared using meta-analytical tools. For studies with missing data, the corresponding authors of those studies were contacted with a request to provide the missing data.

Assessment of quality of studies {#Sec5}
--------------------------------

For the assessment of quality of studies including risk of bias, the National Institute of Health (NIH) tools were used, which were developed jointly by the National Heart, Lung and Blood Institute (NHLBI) and the Research Triangle Institute International \[[@CR12]\]. For the first objective of this systematic review, i.e. to study the GI and hepatic manifestations of COVID-19, the NIH tool for case series was used. It uses nine domains; and based on these, each study was given an overall rating of good, fair, or poor, depending on "yes" response in ≥ 7 domains, 4--6 domains, and \< 4 domains, respectively. For the second objective of this meta-analysis, i.e. to determine the GI and hepatic factors associated with severe clinical course of COVID-19, the NIH tool for case-control studies was used. It uses twelve domains, and based on these, each study was given an overall rating of good, fair, or poor, depending on "yes" response in ≥ 8 domains, 6--7 domains, and \< 6 domains, respectively.

Statistical analysis {#Sec6}
--------------------

The demographic, clinical, and laboratory data was displayed as *n* (%) or mean (standard deviation, \[SD\]). For data with median, interquartile range (IQR), or range, the method described by Wan et al. was used to calculate mean and SD \[[@CR13]\]. The meta-analysis was performed using odds ratios (ORs) with 95% confidence intervals (CIs) as the effect sizes of dichotomous data and a *p*-value of \< 0.05 to show a meaningful difference in the outcomes. To obtain ORs from continuous data (i.e. from standardized mean difference), Hasselblad and Hedges' method was used \[[@CR14]\]. To assess the heterogeneity among studies, *I*^2^ statistic was calculated. An *I*^2^ value \> 50% indicated substantial heterogeneity. To take care of heterogeneity among the studies, and to calculate a more conservative result, the ORs were pooled using only the random-effects model. In addition, if the heterogeneity among the studies was ≥ 50%, a sensitivity analysis was also performed after removing the outlier studies. Review Manager version 5.3.5 software (The Nordic Cochrane Centre, Copenhagen, Denmark) and Microsoft Excel (version 16.35) were employed for the meta-analysis and statistical analyses.

Results {#Sec7}
=======

Study selection and data collection {#Sec8}
-----------------------------------

Using the keywords "2019-nCoV," "nCoV-2019," "novel Coronavirus 2019," "SARS-CoV-2," "COVID-19," "coronavirus," "coronavirus covid-19," and "corona virus" and limiting the Entrez date from 1 January 2020, through 25 March 2020, initially 1672 publications in English language were retrieved from the PubMed database, which were screened for relevance (Fig. [1](#Fig1){ref-type="fig"}). After carefully going through the abstracts and full texts (if needed), of these publications, only 99 potentially relevant studies were evaluated in detail for potential inclusion. Of these, 37 studies were excluded because of the following reasons: (1) 15 studies did not have any data on GI or hepatic manifestations of COVID-19; (2) 9 studies had overlapping patients with other included studies; (3) 4 studies had only radiological or epidemiological data without any clinical data; (4) 2 studies included only pregnant women; (5) 1 study included only those patients who had GI symptoms and excluded patients without GI symptoms; (6) 1 study included only COVID-19-influenza co-infected patients; (7) 1 study included only cancer patients with COVID-19; and (8) 4 studies had data not relevant to present study. Hence, the remaining 62 studies were included in the systematic review. Of these 62 studies, only 26 had comparative data between severe and good clinical course; hence, these 26 studies were included in the meta-analysis (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1PRISMA flow diagram depicting the flow of information through different phases of the systematic review. *PRISMA* Preferred Reporting Items for Systematic Reviews and Meta-Analyses

Characteristics and quality of the included studies {#Sec9}
---------------------------------------------------

The study characteristics of the included 62 studies are given in Table [1](#Tab1){ref-type="table"}. The online publication date of the studies in the PubMed database was from January 24, 2020, through March 25, 2020. Thirty-eight out of 62 (61%) studies were from single centers, while the remaining 24 (39%) were multi-center studies. Most studies (56/62, 90%) were from mainland China, and of the remaining 6 studies, two were from Singapore (3%), and one each (1.6%) from Hong Kong, USA, Australia, and Europe. The total included patients were 8301, and of them, 8076 (97%) were reported from mainland China. The median number of patients included in the studies was 74 (IQR: 34--137). The largest study was by Guan et al. \[[@CR15]\], which recruited 1099 patients from 552 hospitals in 30 provinces, autonomous regions, and municipalities of mainland China.Table 1Characteristics and quality of studies included in systematic review and meta-analysisFirst authorPMIDDate of publicationSetting*N*Clinical courseQuality of studySevereGoodIncluded in systematic reviewIncluded in meta-analysisChan et al. \[[@CR29]\]3198626124-Jan-20Single center in Shenzhen, Guangdong Province, China68Huang et al. \[[@CR30]\]3198626424-Jan-20Single center in Wuhan, Hubei Province, China41132889Chen et al. \[[@CR31]\]3200714330-Jan-20Single center in Wuhan, Hubei Province, China998Song et al. \[[@CR32]\]3202757306-Feb-20Single center in Shanghai, China518Chang et al. \[[@CR33]\]3203156807-Feb-20Three hospitals in Beijing, China138Wang et al. \[[@CR34]\]3203157007-Feb-20Single center in Wuhan, Hubei Province, China1383610289Liu et al. \[[@CR35]\]3204481407-Feb-20Nine tertiary hospitals in Hubei Province, China1378Liu et al. \[[@CR36]\]3204816309-Feb-20Single center in Shenzhen, Guangdong Province, China128Ren et al. \[[@CR37]\]3200416511-Feb-20Single center in Wuhan, Hubei Province, China58Xu et al. \[[@CR38]\]3207578619-Feb-20Seven hospitals in Zhejiang Province, China628Zhang et al. \[[@CR39]\]3207711519-Feb-20Single center in Wuhan, Hubei Province, China140588289Wu et al. \[[@CR40]\]3209141421-Feb-20Two hospitals in Chongqing, China808Yang et al. \[[@CR41]\]3210563224-Feb-20Single center in Wuhan, Hubei Province, China52322089Shi et al. \[[@CR42]\]3210563724-Feb-20Two centers in Wuhan, Hubei Province, China818Xu et al. \[[@CR43]\]3210944325-Feb-20Single center in Beijing, China50133789Yang et al. \[[@CR44]\]3211288426-Feb-20Three tertiary hospitals in Wenzhou City, Zhejiang Province, China1498Huang et al. \[[@CR45]\]3211407427-Feb-20Single center in Wuhan, Hubei Province, China348Xu et al. \[[@CR46]\]3210757728-Feb-20Single center in Guangdong Province, China908Guan et al. \[[@CR15]\]3210901328-Feb-20552 hospitals in 30 provinces, autonomous regions, municipalities, China109917392689Liu et al. \[[@CR47]\]3211864028-Feb-20Three tertiary hospitals in Wuhan, Hubei Province, China78116789Wu et al. \[[@CR48]\]3210927929-Feb-20Multi-center in Jiangsu Province, China808Li et al. \[[@CR49]\]3211861529-Feb-20Single center in Chongqing, China83255889Cao et al. \[[@CR50]\]3212399302-Mar-20Single center in Wuhan, Hubei Province, China102188489Zhang et al. \[[@CR51]\]3212499503-Mar-20Single center in Jinhua, Zhejiang Province, China145Young et al. \[[@CR52]\]3212536203-Mar-20Four hospitals in Singapore1861289Ruan et al. \[[@CR53]\]3212545203-Mar-20Two centers in Wuhan, Hubei Province, China150688289Zhao et al. \[[@CR54]\]3212587303-Mar-20Four institutions in Hunan Province, China101148789Xiong et al. \[[@CR55]\]3213480003-Mar-20Single center in Wuhan, Hubei Province, China428Xiao et al. \[[@CR56]\]3214277303-Mar-20Single center in Guangdong Province, China735Hu et al. \[[@CR57]\]3214669404-Mar-20Single center in Nanjing, Jiangsu Province, China248Zhou et al. \[[@CR58]\]3213468105-Mar-20Single center in Wuhan, Hubei Province, China628Wang et al. \[[@CR59]\]3213946405-Mar-20Single center in Zhengzhou, Henan Province, China186Spiteri et al. \[[@CR60]\]3215632705-Mar-20WHO European region except UK384CNIRST \[[@CR61]\]3215622411-Mar-20Multi-center in Australia714Zhou et al. \[[@CR62]\]3217107611-Mar-20Two hospitals in Wuhan, Hubei Province, China1915413789Liu et al. \[[@CR63]\]3217186611-Mar-20Single center in Hainan Province, China568Chen et al. \[[@CR64]\]3217186911-Mar-20Single center in Shanghai, China2492222789Zhao et al. \[[@CR65]\]3216196812-Mar-20Two hospitals in Anhui Province, China198Chen et al. \[[@CR66]\]3216269912-Mar-20Single center in Anhui Province, China98Zhu et al. \[[@CR67]\]3216718113-Mar-20Two emergency departments in Anhui Province, China328Wu et al. \[[@CR68]\]3216752413-Mar-20Single center in Wuhan, Hubei Province, China2018411789Cheng et al. \[[@CR69]\]3217412814-Mar-20Single center in Shanghai, China118Mo et al. \[[@CR70]\]3217372516-Mar-20Single center in Wuhan, Hubei Province, China155857089Wang et al. \[[@CR71]\]3217677216-Mar-20Single center in Wuhan, Hubei Province, China69145589Wang et al. \[[@CR72]\]3217991017-Mar-20Single center in Shenzhen, Guangdong Province, China558Han et al. \[[@CR73]\]3218167217-Mar-20Single center in Wuhan, Hubei Province, China1087Qian et al. \[[@CR74]\]3218180717-Mar-20Five hospitals in Zhejiang Province, China9198289Gao et al. \[[@CR75]\]3218191117-Mar-20Single center in Fuyang, Anhui Province, China43152889Shi et al. \[[@CR76]\]3218848418-Mar-20Multi-center in Zhejiang Province, China4874943878Arentz et al. \[[@CR77]\]3219125919-Mar-20Single center in Washington State, USA212107Wang et al. \[[@CR78]\]3219158719-Mar-20Single center in Wuhan, Hubei Province, China907Wu et al. \[[@CR79]\]3219946919-Mar-20Single center in Zhuhai, Guangdong Province, China7418567Liu et al. \[[@CR80]\]3219949319-Mar-20Single center in Nanchang, Jiangxi Province, China76304669Zhang et al. \[[@CR81]\]3220528420-Mar-20Multi-center in Zhejiang Province, China6456458189Deng et al. \[[@CR82]\]3220989020-Mar-20Two tertiary hospitals in Wuhan, Hubei Province, China22510911688Wan et al. \[[@CR83]\]3219877621-Mar-20Multi-center in Chongqing, China135409589Zhou et al. \[[@CR84]\]3220938221-Mar-20Single center in Wuhan, Hubei Province, China3482679To et al. \[[@CR85]\]3221333723-Mar-20Two hospitals in Hong Kong23101379Jin et al. \[[@CR86]\]3221355624-Mar-20Multi-center in Zhejiang Province, China651645878Sun et al. \[[@CR87]\]3221175525-Mar-20Single center in Singapore547Shi et al. \[[@CR88]\]3221181625-Mar-20Single center in Wuhan, Hubei Province, China4168Lian et al. \[[@CR89]\]3221184425-Mar-20Multi-center in Zhejiang Province, China78878710883011241/6210 (20%)4969/6210 (80%)*PMID* PubMed identification number, *N* number

The quality of study was assessed using the NIH tool for case series \[[@CR12]\], and the results are shown in Table [1](#Tab1){ref-type="table"}. The scores were as follows: 8/9 (48 studies \[77%\]); 7/9 (8 studies \[13%\]); 6/9 (2 studies \[3%\]); 5/9 (2 studies \[3%\]); and 4/9 (2 studies \[3%\]). Thus, 56 studies (90%) were of good quality (scores of ≥ 7) and the remaining 6 studies (10%) were of fair quality (scores 4--6). None of the included study was judged poor.

Twenty-six studies (4676 patients), which were included in the meta-analysis, were evaluated for quality by NIH tool for case-control studies \[[@CR12]\] (Table [1](#Tab1){ref-type="table"}). The scores were as follows: 9/12 (24 studies \[92%\]) and 8/12 (2 studies \[8%\]). Thus, all the studies were of good quality with scores ≥ 8. Out of the twelve domains assessed by this tool, the three domains in which all the studies were given "0" score were sample size justification, blinding of assessors, and adjusting for confounding variables.

Demographic data and clinical presentation of patients {#Sec10}
------------------------------------------------------

Table [2](#Tab2){ref-type="table"} shows the clinical presentation of the included patients. The total number of patients was 8301, and of these, 4443 (54%) were males. Thus, the male to female ratio was approximately 1.2:1. The pooled mean age of patients was 48.7 ± 16.5 years.Table 2Demographic data and clinical presentation of patientsFirst author*N*AgeGenderComorbiditiesGeneral symptomsGastro-intestinal symptomsMeanSDMaleMale%AnyCLDFeverCoughSputumDyspneaDiarrheaNausea VomitingPain abdomenChan et al. \[[@CR29]\]646.222.53504--54102----Huang et al. \[[@CR30]\]4149.313.130731314031(11/39)(22/40)(1/38)----Chen et al. \[[@CR31]\]9955.513.1676850--8281--3121--Song et al. \[[@CR32]\]5149.016.02549111492410753--Chang et al.\[[@CR33]\]1338.711.61077----1262--1----Wang et al. \[[@CR34]\]13855.319.5755464413682374314143Liu et al. \[[@CR35]\]13754.212.1614527--1126662611----Liu et al. \[[@CR36]\]1253.718.0867701011----22--Ren et al. \[[@CR37]\]553.69.53602155140----Xu et al. \[[@CR38]\]6241.715.2355620748503523----Zhang et al. \[[@CR39]\]14056.511.87151908(110/120)(90/120)--(44/120)(18/139)(24/139)(8/139)Wu et al. \[[@CR40]\]8044.011.0425315--61581177--7Yang et al. \[[@CR41]\]5259.713.3356721--5140--33--2--Shi et al. \[[@CR42]\]8149.511.042522175948153434--Xu et al. \[[@CR43]\]5043.916.82958----4320741----Yang et al. \[[@CR44]\]14945.113.48154--811487482112--Huang et al. \[[@CR45]\]3456.217.114411613217855----Xu et al. \[[@CR46]\]9051.013.8394345--705711--55--Guan et al. \[[@CR15]\]109946.717.164058261239757453702054255--Liu et al. \[[@CR47]\]7842.718.13950----5734----------Wu et al. \[[@CR48]\]8046.115.439493816351--3011--Li et al. \[[@CR49]\]8345.512.3445315--72651597--7Cao et al. \[[@CR50]\]10252.722.653524728350----11----Zhang et al. \[[@CR51]\]1446.820.2750----1310----00--Young et al. \[[@CR52]\]1849.511.59505--1315--23----Ruan et al. \[[@CR53]\]15057.712.51026877412711054110------Zhao et al. \[[@CR54]\]10144.411.6565530--7963--132--Xiong et al. \[[@CR55]\]4249.514.1256013--3627--810----Xiao et al. \[[@CR56]\]7341.216.24156------53----26----Hu et al. \[[@CR57]\]2436.229.9833--052----------Zhou et al. \[[@CR58]\]6252.812.23963----542828159----Wang et al. \[[@CR59]\]1841.020.910566--1710--431--Spiteri et al. \[[@CR60]\]3841.818.52566(2/7)(0/7)(20/31)(14/31)--(2/31)(1/31)(1/31)--CNIRST \[[@CR61]\]7146.019.83651----(22/34)(24/34)--(3/34)(9/34)(2/34)--Zhou et al. \[[@CR62]\]19156.315.71196291--180151445697--Liu et al. \[[@CR63]\]5652.114.73155--14421214--10--Chen et al. \[[@CR64]\]24950.320.91265190221791--198----Zhao et al. \[[@CR65]\]1943.723.2115831159----1----Chen et al. \[[@CR66]\]942.115.35560--87--02--0Zhu et al. \[[@CR67]\]3244.313.21547--227215--1----Wu et al. \[[@CR68]\]20151.312.712864--71881638380------Cheng et al. \[[@CR69]\]1150.415.5873----87311----Mo et al. \[[@CR70]\]15554.018.0865571712697--50733Wang et al. \[[@CR71]\]6946.320.4324625160382020103--Wang et al. \[[@CR72]\]5542.214.72240--177----------Han et al. \[[@CR73]\]10845.013.63835----9465----15----Qian et al. \[[@CR74]\]9147.815.43741----655530102111--Gao et al. \[[@CR75]\]4343.712.12660------------------Shi et al. \[[@CR76]\]48746.019.025953--22--------------Arentz et al. \[[@CR77]\]2170.013.011521811111--17------Wang et al. \[[@CR78]\]9045.014.03337----5520----6--2Wu et al. \[[@CR79]\]7443.53.83953----4537--926----Liu et al. \[[@CR80]\]7648.315.74863----6335--922--Zhang et al. \[[@CR81]\]64545.314.332851(177/468)(25/620)540425225265322--Deng et al. \[[@CR82]\]22555.419.012455127--18985499933----Wan et al. \[[@CR83]\]13546.014.272534321201021218184--Zhou et al. \[[@CR84]\]3464.78.81750------------------To et al. \[[@CR85]\]2358.411.6135711--225--421--Jin et al. \[[@CR86]\]65145.214.4331511782554543522727------Sun et al. \[[@CR87]\]5444.813.9295450--3613720----Shi et al. \[[@CR88]\]41661.012.520549--43341442311716----Lian et al. \[[@CR89]\]78845.814.940752218316365062653788----830148.716.5444354%1957/5785(34%)200/6183(3%)6274/7546(83%)4651/7673(61%)1690/5894(29%)1263/6962(18%)555/6401(9%)182/3629(5%)30/694(4%)*N* number, *SD* standard deviation, *CLD* chronic liver disease

Table [2](#Tab2){ref-type="table"} also shows the clinical presentation and underlying comorbidities of the included patients. Thirty-four percent (1957/5785) of patients had one or more of some chronic underlying comorbidity such as hypertension, diabetes, cardiovascular disease, and chronic kidney disease (individual data not shown). Notably, chronic liver disease (including chronic hepatitis B or C, non-alcoholic steatohepatitis \[NASH\], or cirrhosis) was present in just 3% (200/6183) of patients.

Of the presenting symptoms, fever was the most common, present in 83% (6274/7546) of patients, followed by cough in 61% (4651/7673), expectoration (sputum) in 29% (1690/5894), and dyspnea in 18% (1263/6962) patients. Among the GI symptoms, diarrhea was the most common, present in 9% (555/6401), followed by nausea/vomiting in 5% (182/3629) and abdominal pain in just 4% (30/694) patients (Table [2](#Tab2){ref-type="table"}).

Liver function tests of patients {#Sec11}
--------------------------------

Only 23 studies had data on liver function tests (Table [3](#Tab3){ref-type="table"}). The transaminases, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), were elevated in 25% (559/2226) and 23% (477/2107) patients, respectively. Serum bilirubin was elevated in 9% (130/1471), and prothrombin time (PT) was elevated in just 7% (55/750) patients. Very few studies had data on serum albumin; however, it was below the normal range in 60% (491/817) patients.Table 3Liver function tests of patientsFirst author*N*High ASTHigh ALTHigh bilirubinLow albuminHigh PTChan et al. \[[@CR29]\]600000Huang et al. \[[@CR30]\]4115--------Chen et al. \[[@CR31]\]99352818975Liu et al. \[[@CR36]\]122206--Ren et al. \[[@CR37]\]5--1----1Xu et al. \[[@CR38]\]6210--------Yang et al. \[[@CR41]\]521515------Shi et al. \[[@CR42]\]8143--------Yang et al. \[[@CR44]\]14927184917Huang et al. \[[@CR45]\]347832517Guan et al. \[[@CR15]\]1099(168/757)(158/741)(76/722)----Wu et al. \[[@CR48]\]8033120Ruan et al. \[[@CR53]\]150(54/147)(43/146)(18/147)(114/148)--Hu et al. \[[@CR57]\]24020----Wang et al. \[[@CR59]\]18(4/16)(4/16)------Zhou et al. \[[@CR62]\]191--(59/189)----(11/182)Zhao et al. \[[@CR65]\]19(5/18)(5/18)------Wu et al. \[[@CR68]\]201(59/198)(43/198)(10/198)(195/198)(4/195)Mo et al. \[[@CR70]\]1555454------Wang et al. \[[@CR71]\]691923------Qian et al. \[[@CR74]\]9197--43--Wan et al. \[[@CR83]\]13530--------To et al. \[[@CR85]\]23--4------559/2226 (25%)477/2107 (23%)130/1471 (9%)491/817 (60%)55/750 (7%)*AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *PT* prothrombin time, *N* number

Clinical outcome {#Sec12}
----------------

Since, at the time of publication of most of these studies, many of the included patients were still admitted in the hospital, with many in the ICUs, it was not possible by many studies to provide the mortality data. However, many studies did classify the patients into severe and non-severe groups based on pre-defined criteria \[[@CR9]--[@CR11]\]. Overall, 30 studies reported that 80% (4969/6210) of their patients had good clinical course, while the remaining 20% (1241/6210) patients had severe clinical course based on pre-defined severity criteria \[[@CR9]--[@CR11]\], including admission to ICU, development of ARDS, ventilatory requirement, or mortality (Table [1](#Tab1){ref-type="table"}).

Factors associated with severe clinical course: age and comorbidity {#Sec13}
-------------------------------------------------------------------

Age was compared between patients with severe clinical course and good clinical course in 26 studies. The mean age in patients with severe clinical course was found to be significantly higher than in patients with good clinical course (60 ± 16 vs. 46 ± 16 years; *p* \< 0.01). The pooled OR of patients of advanced age (≥ 60 years) having severe clinical course was 3.96 (95% CI, 3.24--4.84; *p* \< 0.01) (Fig. [2](#Fig2){ref-type="fig"}). The heterogeneity among the studies was substantial with an *I*^2^ of 95%. A sensitivity analysis after removing 7 outlier studies revealed a higher pooled odds ratio of 4.19 (95% CI, 3.18--5.53; *p* \< 0.01) and an acceptable *I*^2^ of 42%.Fig. 2Forest plot showing pooled odds ratio for patients with higher age (≥ 60 years) developing severe clinical course

Presence of any comorbidity was assessed as a factor associated with severe clinical course in 16 studies. The pooled OR of 3.88 (95% CI, 2.92--5.13; *p* \< 0.01) suggested that the presence of any comorbidity was significantly associated with severe clinical course (Fig. [3](#Fig3){ref-type="fig"}). The heterogeneity among studies was acceptable with an *I*^2^ of 42%.Fig. 3Forest plot showing pooled odds ratio for patients having any comorbidity developing severe clinical course

GI and hepatic factors associated with severe clinical course {#Sec14}
-------------------------------------------------------------

Presence of underlying chronic liver disease, as a factor associated with severe clinical course, was assessed in 10 studies, and it was not found to be significantly associated (pooled OR 1.07 \[95% CI, 0.55--2.09; *p* = 0.83\]) (Fig. [4](#Fig4){ref-type="fig"}). There was no heterogeneity among the studies (*I*^2^ = 0%).Fig. 4Forest plot showing pooled odds ratio for patients with chronic liver disease developing severe clinical course

Among the GI symptoms, diarrhea was found in 9% of cases. Whether it was associated with severe clinical course was assessed in 16 studies. A pooled OR of 2.00 (95% CI, 1.37--2.91; *p* \< 0.01) indicated that it was significantly associated with severe clinical course (Fig. [5](#Fig5){ref-type="fig"}). There was non-significant heterogeneity among studies with an *I*^2^ of 22%.Fig. 5Forest plot showing pooled odds ratio of diarrhea being associated with severe clinical course

Transaminases, AST and ALT values, were reported to be associated with severe clinical course by many individual studies. AST was evaluated in 15 studies, and higher than normal values of AST was found to be significantly associated with severe clinical course (pooled OR 1.40 \[95% CI, 1.25--1.56\]; *p* \< 0.01) (Fig. [6](#Fig6){ref-type="fig"}). The heterogeneity among studies was substantial (*I*^2^ of 91%) so a sensitivity analysis was done after removing four outlier studies, which again revealed a significant pooled OR of 2.45 (95% CI, 1.83--3.28; *p* \< 0.01) and an acceptable *I*^2^ of 31%. ALT was evaluated in 16 studies, and higher than normal values of ALT was found to be significantly associated with severe clinical course (pooled OR 1.57 \[95% CI, 1.22--2.04; *p* \< 0.01\]) (Fig. [7](#Fig7){ref-type="fig"}). Since the heterogeneity among the studies was high (*I*^*2*^ 68%), a sensitivity analysis was done after removing one outlier study, which still revealed a significant pooled OR of 1.68 (95% CI, 1.39--2.04; *p* \< 0.01) and an *I*^2^ of just 8%.Fig. 6Forest plot showing pooled odds ratio of higher than normal values of aspartate aminotransferase being associated with severe clinical courseFig. 7Forest plot showing pooled odds ratio of higher than normal values of alanine transaminase being associated with severe clinical course

Serum bilirubin was assessed in 7 studies, and higher than normal values of serum bilirubin was found to be significantly associated with severe clinical course with a pooled OR of 2.38 (95% CI, 1.76--3.22; *p* \< 0.01) (Fig. [8](#Fig8){ref-type="fig"}). The heterogeneity among the studies was non-significant with an *I*^2^ of 25%.Fig. 8Forest plot showing pooled odds ratio of higher than normal values of serum bilirubin being associated with severe clinical course

Serum albumin was assessed in 10 studies, and lower than normal values of serum albumin was found to be significantly associated with severe clinical course with a pooled OR of 3.40 (95% CI, 2.35--4.92; *p* \< 0.01) (Fig. [9](#Fig9){ref-type="fig"}). Since the heterogeneity among studies was substantial with an *I*^2^ of 93%, a sensitivity analysis was done after removing two outlier studies, which again revealed a significant pooled OR of 5.09 (95% CI, 3.75--6.91; *p* \< 0.01) and an acceptable *I*^2^ of 25%.Fig. 9Forest plot showing pooled odds ratio of lower than normal values of serum albumin being associated with severe clinical course

PT as a factor associated with severe clinical course was evaluated in 8 studies. Higher than control values of PT was found to be significantly associated with severe clinical course with a pooled OR of 2.95 (95% CI, 1.61--5.38; *p* \< 0.01) (Fig. [10](#Fig10){ref-type="fig"}). Since the heterogeneity among studies was significant with an *I*^2^ of 69%, a sensitivity analysis was done after removing one outlier study, which again showed a significant pooled OR of 3.81 (95% CI, 2.68--5.41; *p* \< 0.01) and non-significant *I*^2^ of 13%.Fig. 10Forest plot showing pooled odds ratio of higher than normal values of prothrombin time being associated with severe clinical course

Discussion {#Sec15}
==========

To summarize the results of this systematic review and meta-analysis, the mean age of patients with COVID-19 is 48.7 ± 16.5 years with a male to female ratio of 1.2:1. Common symptoms and their frequency are fever (83%), cough (61%), expectoration (29%), and dyspnea (18%). Among the GI symptoms, diarrhea was the most common, present in 9%, followed by nausea/vomiting in 5%, and pain abdomen in just 4% of patients. Transaminases were abnormal in approx. 25%, serum albumin was low in 60%, bilirubin was high in 9%, and prothrombin time was abnormal in 7%. Twenty percent of patients developed severe clinical course, and two of the most common factors associated with severe clinical course are age ≥ 60 years (OR approximately \[approx.\] 4) and underlying chronic comorbidity (OR approx. 4). However, underlying chronic liver disease was not associated with severe clinical course. Presence of diarrhea was associated with severe clinical course (OR 2). Liver function abnormalities were associated with severe clinical course: high AST (OR approx. 2), high ALT (OR approx. 1.7), high bilirubin (OR approx. 2), low albumin (OR approx. 5), and high PT (OR approx. 4).

The strength of this systematic review and meta-analysis is that it included a large number of studies: 62 studies involving 8301 patients for the data on demographic and clinical features (especially GI and hepatic) and 26 studies involving 4676 patients for meta-analysis of GI and hepatic factors associated with severe clinical course. This is one of the first meta-analyses on factors associated with severe clinical course. The results of our study show that, even though COVID-19 is a disease of predominantly respiratory system, however, the involvement of the digestive system is also common, and it portends severe clinical course, including ICU requirement, or even mortality.

Our study showed that although GI symptoms are not very common, they can still occur in up to 10% of patients. However, it is still unclear how the SARS-CoV-2 virus induces GI symptoms and whether SARS-CoV-2 can be transmitted through the GI tract \[[@CR16]\]. The SARS-CoV-2 virus has been documented in fecal samples as well as in intestinal mucosa of infected patients, and this may indicate that GI symptoms are a result of invasion of GI tract by SARS-CoV-2 as an alternative route of infection. SARS-CoV-2 uses angiotensin-converting enzyme-2 (ACE2) as a viral receptor to enter host cells \[[@CR17]\], and these receptors are not only highly expressed in the small intestine, especially in the proximal and distal enterocytes \[[@CR18]\], but also an important regulator of intestinal inflammation \[[@CR19]\]. The SARS-CoV-2 infection of the ACE2-expressing enterocytes leads to mucosal inflammation, malabsorption, unbalanced intestinal secretion, and activation of the enteric nervous system, resulting in diarrhea. Other indirect mechanisms of GI involvement in COVID-19 could be damage of the GI mucosa through a chain of inflammatory responses; drugs-induced (especially antibiotics) diarrhea; and changes in the composition and function of intestinal microbiota that mutually affect the respiratory tract through immune regulation, the so-called "gut-lung axis" \[[@CR20], [@CR21]\]. Whatever be the mechanism of GI involvement, the implication of diarrhea and prolonged fecal shedding of SARS-CoV-2 viral particles (even after clinical recovery), is the potential for fecal-oral transmission of COVID-19, especially in countries with poor sanitation \[[@CR22], [@CR23]\]. Hence, a negative stool sample should be a mandatory criterion before discharging a patient from the hospital.

The pathogenesis of hepatic involvement may also be multi-factorial. It has been shown previously that cholangiocytes may too express ACE2 receptors \[[@CR24]\]; and so it has been speculated that SARS-CoV-2 infection might cause bile duct involvement rather than hepatocellular involvement. However, significant increases in circulating levels of serum gamma-glutamyl transferase, alkaline phosphatase, or bilirubin have been rarely reported in COVID-19 patients. In addition, liver histopathologic features from COVID-19 patients also did not show any significant damage in hepatocytes or bile duct cells. For this reason, it is hypothesized that COVID-19-related liver dysfunction is more likely due to secondary liver damage rather than primary cholangiocyte or hepatocyte damage by SARS-CoV-2. The secondary mechanisms of COVID-19-related liver dysfunction could be systemic inflammatory response syndrome (SIRS); sepsis; hypoxia-reperfusion dysfunction; and drug-induced liver injury (DILI) as a result of hepatotoxic drugs used to treat COVID-19 \[[@CR25]\]. SIRS is a result of sudden initiation of an inflammatory cascade due to the activation of both natural and cellular immunity triggered by COVID-19 infection. Hyperactivated immune responses and cytokine storm--related systemic inflammation in SARS-CoV-2 infection can affect and damage many organs, including the gut and liver \[[@CR26]\]. In addition to SIRS, sepsis is also not uncommon in severe and critical COVID-19 cases. The pathophysiology of sepsis-related liver injury includes cholestasis due to altered bile metabolism, hepatocellular injury due to drug toxicity, or overwhelming inflammatory hypoxic liver injury due to ischemia and shock \[[@CR27]\]. Furthermore, severe hypoxia and hypovolemia could be the major causes of ischemic liver injury in COVID-19 cases with hypotension and shock. Ischemic hepatic injury is associated with metabolic acidosis, calcium overloading, and changes of mitochondrial membrane permeability, and has thus far usually manifested as high aminotransferase concentrations in serum \[[@CR26]\]. In addition, many patients with COVID-19 have a history of simultaneous use of multiple antiviral, antimalarial, and antibiotic drugs, which are potentially hepato-toxic, such as oseltamivir, abidol, lopinavir/ritonavir, hydroxychloroquine, and azithromycin. Thus, DILI may be an additional factor in liver function derangement \[[@CR28]\].

Our meta-analysis had a few limitations. The first limitation was that several of the identified factors may be confounding variables, and which of these factors are independently associated with severe clinical course could not be determined. Since our meta-analysis included only retrospective case series with a lot of heterogeneity, identification of independent factors was not possible. Only a well-designed prospective study can identify independent factors associated with severe clinical course or mortality. The second limitation was the non-uniformity of the clinical endpoint. It may be argued that clubbing studies that compared patients with and without ICU admission with studies that used mortality as endpoint may not be statistically justified. However, in the present circumstances, when many of the included patients are still admitted and sufficient follow-up time has still not elapsed to determine their final outcome, using a composite endpoint of "severe clinical course" seems to be the most acceptable endpoint in our meta-analysis. The third limitation is that most studies in this meta-analysis are from China. COVID-19 is now a global disease; however, at the time of data extraction and analysis very few non-China studies were published. This meta-analysis will need updating when more studies from other countries become available.

In conclusion, our systematic review and meta-analysis has shown that, even though GI and hepatic manifestation are not very common in COVID-19, their presence portends a severe clinical course. GI symptoms, especially diarrhea, should be enquired from patients because it not only indicates severe disease, these patients are more likely to have fecal shedding of virus with potential infectivity to others. In addition, liver function tests in COVID-19 patients need to be monitored, which are likely to be abnormal in up to one-fourth of patients, especially those with severe clinical course.
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